Read and report vaccine reactions, harassment and failures.
Selected NVIC statements & commentaries related to Respiratory Syncytial Virus (RSV) or RSV vaccine
NVIC Newsletter Articles
Wrangham T. Vote to Add Drug to Childhood Vaccination Schedule Opens Door to Daycare Mandates, Tracking, and Injury Liability Shield. Aug. 10, 2023.
Wrangham T, Jolly J. FDA Committee to Vote on New RSV Vaccine Targeting Pregnant Women & Babies. May 3, 2023.
The Vaccine Reaction News Journal
Parpia R. RSV Vaccines for Senior Adults Linked to Guillain-Barré Syndrome. Mar. 11, 2024.
Parpia R. CDC Reports Errors in RSV Vaccines Given to Pregnant Woman, Monoclonal Antibody Shots to Children. Feb. 5, 2024.
Baker A. Twelve Infants Die During Clinical Trials for FDA-Endorsed RSV Drug. June 19, 2023.
Baker A. RSV Vaccine Approved by FDA for Adults 60 and Older. May 29, 2023.
Hobley N. Guillain-Barré Syndrome Linked to the RSV Vaccine. Mar. 14, 2023.
Hobley, N. Pfizer’s New RSV Vaccine for Pregnant Women on Fast Track. Nov. 22, 2022.
IMPORTANT NOTE: NVIC encourages you to become fully informed about Respiratory Syncytial Virus (RSV) and the Respiratory Syncytial Virus (RSV) vaccine by reading all sections in the Table of Contents, which contain many links and resources such as the manufacturer product information inserts, and to speak with one or more trusted health care professionals before making a vaccination decision for yourself or your child. This information is for educational purposes only and is not intended as medical advice.